Ozempic Now Co-Payable in Portugal for Obesity & Cardiovascular Risk

Access to Ozempic, a medication used in the treatment of type 2 diabetes, has been expanded following a decision by the Infarmed, the Portuguese Authority for Medicines and Health Products. The authorization now includes coverage for patients with obesity or a high risk of cardiovascular disease, broadening access to a treatment considered essential for many.

Expanded Coverage Details

According to the Infarmed’s recently released Report on Public Funding Evaluation, Ozempic’s coverage has been authorized for “the treatment of adults with type 2 diabetes mellitus, insufficiently controlled, with a BMI equal to or greater than 30 kg/m2 or a high risk of cardiovascular disease.” The medication will be used alongside diet and exercise, and in addition to other diabetes treatments, as a second or third-line therapy.

Did You Know? Ozempic’s coverage is authorized for adults with a Body Mass Index (BMI) of 30 kg/m2 or higher, or those at elevated risk of cardiovascular disease.

The decision has been welcomed by José Manuel Boavida, president of the Portuguese Diabetes Association (APDP), who described it as “a long-standing demand of the association.” Boavida stated that previously, there was “a discrimination between people with diabetes which was in no way acceptable.”

Addressing Disparities

Boavida explained that the expanded coverage will now benefit “the majority of people with diabetes, all those who have obesity and all those who present a high cardiovascular risk, which are practically all people with diabetes.” The APDP believes this decision creates “a situation of non-discrimination between people with diabetes.”

Expert Insight: This decision represents a significant step towards equitable access to a medication that can improve health outcomes for a broader range of individuals living with type 2 diabetes and related health risks.

However, the APDP also notes that further steps are needed, specifically “the direct approach to the problem of obesity.” Boavida acknowledged the complexity of addressing obesity but stated, “it will also have to be done. We will take steps.”

Frequently Asked Questions

What condition is Ozempic used to treat?

Ozempic is used in the treatment of type 2 diabetes mellitus.

Who is now eligible for Ozempic coverage?

Adults with type 2 diabetes, insufficiently controlled, with a BMI equal to or greater than 30 kg/m2 or a high risk of cardiovascular disease are now eligible.

What did the president of the APDP say about the decision?

José Manuel Boavida called the decision “a long-standing demand of the association” and stated that it addresses a previous “discrimination between people with diabetes.”

What impact will expanded access to medications like Ozempic have on public health initiatives focused on diabetes and obesity management?